Business Context and Reporting Period
Company: Bon Natural Life Ltd (Ticker: BON)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended September 30, 2025
Business Overview: Bon Natural Life is a Cayman Islands holding company conducting operations primarily in China through PRC subsidiaries. The company manufactures and sells natural functional ingredients, fragrance compounds, and health supplements. Key products include stachyose, apple polyphenol, and ambroxide. The company operates under a dual-class share structure following a 1-for-25 reverse stock split effective May 2025.
Key Financial Metrics
| Metric | 2025 (USD) | 2024 (USD) | Change |
|---|---|---|---|
| Revenue | $18,670,684 | $23,844,556 | -21.7% |
| Gross Profit | $3,878,821 | $7,110,009 | -45.4% |
| Gross Margin | 20.8% | 29.8% | -9.0 pts |
| Net Loss | $(2,049,431) | $345,248 | Turned to Loss |
| EPS (Basic) | $(0.72) | $4.17 | N/A |
| Total Assets | $85,185,615 | $61,765,432 | +37.9% |
| Total Liabilities | $27,187,876 | $17,415,893 | +56.1% |
| Working Capital | $19,451,991 | $13,348,025 | +45.7% |
| Cash & Restricted Cash | $6,265,978 | $658,610 | +851.4% |
| Outstanding Debt | $12,172,653 | $6,690,319 | +81.9% |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 21.7% primarily due to a 50.6% drop in health supplement sales and a 40.3% drop in bioactive food ingredient revenue, despite a 63.5% increase in fragrance compound sales. The decline was driven by strategic price reductions to gain market share and a shift in sales focus.
- Margin Compression: Gross margin fell from 29.8% to 20.8% due to downward price adjustments on bioactive ingredients and fragrance compounds to respond to market competition.
- Operating Expenses: Total operating expenses increased 5.1% to $5.5 million. General and administrative expenses rose 28.9% due to increased professional fees and share-based compensation ($606k). R&D expenses decreased 53.5% as the company shifted to outsourcing specific projects.
- Liquidity Improvement: Cash and restricted cash increased significantly to $6.3 million, driven by net proceeds of $10.7 million from a public offering in March 2025 and $5.6 million from a private placement in May 2024.
- Debt Increase: Total debt obligations increased to approximately $12.2 million, consisting of short-term and long-term bank loans, to support working capital and expansion.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects to utilize cash reserves and proceeds from recent offerings to fund sales network expansion, R&D, and production capacity expansion. The company plans to focus on the "Big Health" market, specifically human micro-biome health. No specific financial guidance was provided for future periods.
Key Risks & Contingencies:
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to a lack of accounting staff with U.S. GAAP expertise. Remediation is ongoing, including the appointment of a new CFO in November 2025.
- Regulatory Risks (China): Significant risks exist regarding PRC regulations on overseas listings, cybersecurity reviews, and foreign exchange controls. The company faces potential delisting risks under the Holding Foreign Companies Accountable Act (HFCAA) if its auditor cannot be inspected by the PCAOB, though it currently uses a U.S.-based auditor.
- Customer Concentration: Two customers accounted for 40% of total revenue in 2025. Loss of these customers could materially impact operations.
- Product Liability: Products are not clinically proven to treat diseases. Negative publicity or product liability claims could harm the brand.
- Capital Needs: Management estimates capital needs for expansion at approximately $30 million, requiring additional financing.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation for material weaknesses in internal controls and the effectiveness of the new CFO and accounting staff.
- Revenue Quality: Assess the sustainability of revenue growth given the significant price cuts and the high concentration of revenue in two major customers.
- Debt Servicing: Review the terms of the $12.2 million in outstanding debt, including maturity dates and interest rates, to ensure liquidity is sufficient for upcoming repayments.
- Regulatory Compliance: Monitor the status of PRC regulatory filings and the PCAOB inspection status of the auditor to assess delisting risks.
- Share-Based Compensation: Evaluate the impact of significant share-based compensation expenses (approx. $1.4 million in 2025) on future earnings and dilution.